Literature DB >> 8179071

Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.

S W Bell1, R L Kempson, M R Hendrickson.   

Abstract

A recent trend in the classification of uterine smooth muscle neoplasms (USMNs) into clinically benign and clinically malignant groups has been to move from exclusive reliance upon mitotic index (MI) to an approach that incorporates additional histopathologic characteristics. In furtherance of this goal, we assessed a variety of histopathologic features of 213 problematic smooth muscle neoplasms for which we had > or = 2 years of clinical follow-up data or for which there was an unfavorable outcome. One hundred and thirteen of these patients have had a minimum follow-up of 5 years, and 48 have been followed for > or = 10 years. Cases eliminated from the study group included USMNs with a significant myxoid or epithelioid component and cases of intravenous leiomyomatosis. USMNs, whether cellular or not, with no cytologic atypia and with a mitotic index (MI = number of mitotic figures [mf]/10 high-power fields [hpf]) of < 5 mf/10 hpf (usual leiomyomas) were also excluded unless they had unusual features or were associated with an adverse clinical outcome. Fifty-six patients were initially treated by myomectomy or another form of local tumor removal; the remainder had a hysterectomy. From a wide variety of light microscopic features assessed, the important predictors that emerged, using a variety of data exploratory techniques, were MI, the degree of cytologic atypia, and the presence or absence of coagulative tumor cell necrosis (CTCN). Stratification of the USMNs with respect to these three features resulted in a five-group classification of USMNs with the following major characteristics. Group 1: Of the 89 USMNs with an MI in the range 5 < or = MI < 20 without CTCN and with no more than mild atypia, 88 were clinically benign. One patient with a tumor in this group died of metastatic disease 96 months after her uterine cervical primary neoplasm was removed. Combining our data with that in the literature, the failure rate in this group is approximately 1/200 (0.5%). This low failure rate warrants the use of the label "leiomyoma with increased mitotic index" for USMNs with these histologic features. Two patients whose USMNs were characterized by mild atypia, no necrosis, and MI < 5 developed identical-appearing pulmonary metastases and were judged in retrospect to have the syndrome "benign metastasizing leiomyoma." Group 2: USMNs with no CTCN and diffuse moderate to severe atypia fell into two groups based on the MI. For those patients whose neoplasms had an MI > or = 10 mf/10 hpf, four of 10 failed.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8179071

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  119 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.

Authors:  Zehra Ordulu; Paola Dal Cin; Wilson W S Chong; Kwong Wai Choy; Charles Lee; Michael G Muto; Bradley J Quade; Cynthia C Morton
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

3.  Different characteristics of mitochondrial microsatellite instability between uterine leiomyomas and leiomyosarcomas.

Authors:  Jae-Ho Lee; Tae-Yung Ryu; Chi-Heum Cho; Dae-Kwang Kim
Journal:  Pathol Oncol Res       Date:  2010-09-18       Impact factor: 3.201

4.  The predictive value of preoperative 18F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour.

Authors:  Kanae Kawai Miyake; Yuji Nakamoto; Yoshiki Mikami; Shiro Tanaka; Tatsuya Higashi; Eiji Tadamura; Tsuneo Saga; Shunsuke Minami; Kaori Togashi
Journal:  Eur Radiol       Date:  2016-02-06       Impact factor: 5.315

5.  A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.

Authors:  Oliver Zivanovic; Lindsay M Jacks; Alexia Iasonos; Mario M Leitao; Robert A Soslow; Emanuela Veras; Dennis S Chi; Nadeem R Abu-Rustum; Richard R Barakat; Murray F Brennan; Martee L Hensley
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

Review 6.  Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis.

Authors:  Markku Miettinen
Journal:  Mod Pathol       Date:  2014-01       Impact factor: 7.842

Review 7.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

8.  Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Authors:  Sabrina Croce; Agnes Ribeiro; Celine Brulard; Jean-Christophe Noel; Frederic Amant; Eberhard Stoeckle; Mojgan Devouassoux-Shisheborah; Anne Floquet; Laurent Arnould; Frederic Guyon; Florence Mishellany; Delphine Garbay; Tine Cuppens; Michal Zikan; Agnès Leroux; Eric Frouin; Pierre Duvillard; Philippe Terrier; Isabelle Farre; Isabelle Valo; Gaetan M MacGrogan; Frederic Chibon
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

9.  Fumarate Hydratase Mutations and Alterations in Leiomyoma With Bizarre Nuclei.

Authors:  Qing Zhang; Kate Poropatich; Julianne Ubago; Jia Xie; Xiuhua Xu; Norma Frizzell; Julie Kim; Beihua Kong; Jian-Jun Wei
Journal:  Int J Gynecol Pathol       Date:  2018-09       Impact factor: 2.762

10.  External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.

Authors:  Alexia Iasonos; Emily Z Keung; Oliver Zivanovic; Rosanna Mancari; Michele Peiretti; Marisa Nucci; Suzanne George; Nicoletta Colombo; Silvestro Carinelli; Martee L Hensley; Chandrajit P Raut
Journal:  Cancer       Date:  2013-03-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.